Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating ...

Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in 3D human tissue models, has reached an agreement to sell its FXR program, including the lead asset FXR314 ...

During the X2 Technology Demonstration, the S-97 Raider performed a flight display to show the capabilities the X2 technology. On Feb. 12, 2025, during the second day of the X2 Technology ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Portions of Interstate 97 were shut down for hours Friday afternoon amid a vehicle fire in Anne Arundel County.Check LIVE traffic map hereFire officials told 11 News that a van fire spread to ...

"We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an ...

Here’s how it went. After the U.S. Army’s FARA program was cancelled in 2024, Sikorsky has continued to work on its S-97 Raider demonstrator. As the Raider’s underlying X2 technology is now ...